University of Kent launches Sirius Proteins start‑up to cut protein production costs

A new spin‑out from the University of Kent, Sirius Proteins, was officially registered this month to bring forward a patented biotechnology platform that simplifies and reduces the cost of producing therapeutic proteins. The company will focus on scaling the technology that enables more efficient synthesis of proteins used in cancer therapies, vaccines and diagnostic assays, moving the university‑developed process from laboratory research toward commercial application.

The launch of Sirius Proteins marks a key step in translating Kent’s intellectual property into market‑ready solutions, potentially expanding access to biologics by lowering production expenses. Industry observers note that the venture could accelerate the availability of protein‑based treatments and tests, while the university anticipates further collaborations and investment to support the start‑up’s growth and regulatory progress.